Veeva Systems stock price target raised to $310 by UBS on strong outlook

Veeva Systems (VEEV) reported robust second-quarter results, exceeding revenue and EPS estimates while raising full-year guidance, prompting multiple analyst firms to increase their price targets. UBS raised its target to $310 from $285, maintaining a Neutral rating due to valuation concerns at 27 times calendar year 2026 free cash flow, despite the strong performance and positive outlook. Other firms, including Piper Sandler ($355), Stifel ($320), and Raymond James ($340), also raised targets, collectively underscoring Veeva's solid market position and continued growth potential within the life sciences cloud software sector.

Analysis

Veeva Systems (VEEV) delivered a robust second-quarter performance, characterized by a 17% year-over-year revenue increase to $789.1 million, which surpassed analyst forecasts by approximately $21 million. Earnings per share also demonstrated significant strength, growing 22% year-over-year to $1.99, beating consensus estimates by 5%. This strong execution prompted the company to raise its full-year guidance for both revenue and billings, signaling management's confidence in future performance. The positive results triggered a wave of price target upgrades from multiple analyst firms, including Piper Sandler, Stifel, and Raymond James. However, a note of caution is warranted. UBS, while raising its price target to $310, maintained a Neutral rating, citing a demanding valuation at 27 times calendar year 2026 free cash flow as a potential cap on further stock appreciation. Furthermore, Evercore ISI highlighted that billings fell slightly short of expectations, a critical detail that contrasts with the company's optimistic full-year billings guidance.

Key Decisions for Investors

• Investors should weigh the company's strong execution, demonstrated by significant revenue and EPS beats and raised full-year guidance, against the high valuation cited by UBS, which may limit further upside.
• The slight miss on quarterly billings, despite positive forward guidance, is a key metric to monitor in subsequent reports to validate the growth trajectory and justify the stock's premium valuation.
• Given the largely bullish analyst sentiment and multiple price target increases, existing holders may find justification to maintain their positions, while new investors should assess their tolerance for the valuation risk.